GlassScriptPhysician profile
Gregory S Guion
NPI 1154937910
$6,368.19
in general payments reported to CMS, 2019-2025
25 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,164 · 2022: $1,878 · 2023: $1,858 · 2024: $1,005 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,842.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $730.62 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $701.82 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.52 | 2021-2023 | |
| Axsome Therapeutics, INC. | $277.25 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $259.98 | 2021-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $252.63 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $208.73 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $178.27 | 2021-2023 | Jornay Pm |
| Lundbeck LLC | $156.76 | 2021-2024 | Rexulti |
| Tris Pharma INC | $146.32 | 2022-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $115.06 | 2022-2024 | Fanapt, Hetlioz |
| Janssen Scientific Affairs, LLC | $106.07 | 2023 | Spravato |
| Corium, LLC | $102.58 | 2023-2025 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $83.80 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $78.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.96 | 2024 | |
| Avanir Pharmaceuticals, INC. | $56.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.36 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $41.56 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $37.67 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $24.76 | 2022 | |
| Almatica Pharma LLC | $23.42 | 2025 | Loreev Xr |
| Neos Therapeutics, LP | $23.34 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Guion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.